Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $2.3900 (6.7%) ($2.2600 - $2.4300) on Thu. Apr. 28, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.16% (three month average) | RSI | 34 | Latest Price | $2.3900(6.7%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -2.1% a day on average for past five trading days. | Weekly Trend | HTBX declines -8.4% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) SMH(98%) BLOK(97%) XOP(90%) XLC(89%) IBB(81%) | Factors Impacting HTBX price | HTBX will decline at least -2.58% in a week (0% probabilities). FXI(-44%) LIT(-89%) XLRE(-47%) BWX(-64%) IGOV(-42%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.58% (StdDev 5.16%) | Hourly BBV | 1.7 () | Intraday Trend | 5.8% | | | |
|
1 - 5 Day Possible Target | $-15.02(-728.45%) | Resistance Level | $2.73 | 5 Day Moving Average | $2.36(1.27%) | 10 Day Moving Average | $2.56(-6.64%) | 20 Day Moving Average | $2.73(-12.45%) | To recent high | -24.1% | To recent low | 13.8% | Market Cap | $263m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |